<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="232774">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00045786</url>
  </required_header>
  <id_info>
    <org_study_id>CC-1088-MDS-801-001</org_study_id>
    <nct_id>NCT00045786</nct_id>
  </id_info>
  <brief_title>Study to Determine the Safety and Preliminary Efficacy of CC-1088 in the Treatment of Myelodysplastic Syndromes</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celgene</source>
  <brief_summary>
    <textblock>
      The primary objective of the study is to assess the safety of CC-1088 to patients with
      myelodysplastic syndromes (MDS).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2001</start_date>
  <completion_date>November 2005</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <enrollment>39</enrollment>
  <condition>Myelodysplastic Syndrome</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CC-1088</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  Eligible patients must have a diagnosis of MDS of at least 12 weeks that is not
             therapy related.

          -  Patient must be able to adhere to the study visit schedule and other protocol
             requirements.

          -  Patient must understand and voluntarily sign an informed consent document.

          -  Women of childbearing potential (WCBP) must have a negative serum or urine pregnancy
             test.

          -  Women must not be pregnant or lactating.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Rush-Presbyterian-St Luke's Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612-3515</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2004</verification_date>
  <lastchanged_date>June 23, 2005</lastchanged_date>
  <firstreceived_date>September 9, 2002</firstreceived_date>
  <keyword>myelodysplastic syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
